24.02

1.11% -0.27

After Hours: 23.55 -0.47 -1.96%

Viridian Therapeutics Inc (VRDN)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Viridian Therapeutics Inc stock is traded at $24.02, with a volume of 1.13M. It is down -1.11% in the last 24 hours and up +24.65% over the past month. Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.

Previous Close:

$24.29

Open:

$24.35

24h Volume:

1.13M

Relative Volume:

0.57

Market Cap:

$2.72B

Revenue:

$70.92M

Net Income/Loss:

$-342.21M

P/E Ratio:

-6.3808

EPS:

-3.7644

Net Cash Flow:

$-304.30M

1W Performance:

+4.03%

1M Performance:

+24.65%

6M Performance:

-18.30%

1Y Performance:

+24.94%

1-Day Range:

$24.00

$24.39

1-Week Range:

$22.84

$24.86

52-Week Range:

$13.18

$34.29

Viridian Therapeutics Inc Stock (VRDN) Company Profile

Name

Viridian Therapeutics Inc

Sector

Healthcare (1033)

Industry

Biotechnology (582)

Phone

617.272.4600

Address

221 CRESCENT STREET, WALTHAM

Employee

252

Twitter

Next Earnings Date

2026-08-05

Latest SEC Filings

VRDN's Discussions on Twitter

Compare VRDN vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
VRDN Viridian Therapeutics Inc	24.02	2.78B	70.92M	-342.21M	-304.30M	-3.7644
VRTX Vertex Pharmaceuticals Inc	547.59	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	828.50	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,011.11	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	138.89	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	211.58	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Viridian Therapeutics Inc Stock (VRDN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-10-25	Reiterated	Wedbush	Outperform
Dec-03-25	Initiated	William Blair	Outperform
Nov-24-25	Initiated	Truist	Buy
Aug-25-25	Resumed	Jefferies	Buy
Dec-19-24	Downgrade	Wells Fargo	Overweight → Equal Weight
Nov-25-24	Initiated	TD Cowen	Buy
Sep-11-24	Reiterated	Needham	Buy
Jun-11-24	Initiated	Wolfe Research	Outperform
Jun-06-24	Initiated	Goldman	Buy
May-09-24	Downgrade	B. Riley Securities	Buy → Neutral
May-09-24	Downgrade	Ladenburg Thalmann	Buy → Neutral
Jun-14-23	Initiated	BTIG Research	Buy
Jun-14-23	Resumed	Credit Suisse	Outperform
May-30-23	Initiated	RBC Capital Mkts	Outperform
Apr-17-23	Initiated	Wells Fargo	Overweight
Mar-30-23	Initiated	Stifel	Buy
Dec-19-22	Initiated	Cowen	Outperform
Dec-19-22	Initiated	Needham	Buy
Dec-16-22	Initiated	Credit Suisse	Outperform
Dec-01-22	Initiated	H.C. Wainwright	Buy
Jun-23-22	Initiated	B. Riley Securities	Buy
Nov-18-21	Initiated	SVB Leerink	Outperform
Oct-12-21	Initiated	Evercore ISI	Outperform
Jan-25-21	Initiated	Ladenburg Thalmann	Buy

View All

Viridian Therapeutics Inc Stock (VRDN) Latest News

Aug 21, 2026

260,000 Shares in Viridian Therapeutics, Inc. $VRDN Purchased by Blue Owl Capital Holdings LP - MarketBeat

Aug 21, 2026

Aug 20, 2026

Deep Track Capital, LP Trims Viridian Therapeutics (VRDN) Stake in Strategic Rebalancing - GuruFocus

Aug 20, 2026

Viridian Therapeutics CLO Jennifer Tousignant sells $348,194 in shares By Investing.com - Investing.com Canada

Aug 20, 2026

Viridian Therapeutics CLO Jennifer Tousignant sells $348,194 in shares - Investing.com

Aug 20, 2026

Viridian Therapeutics (NASDAQ:VRDN) Insider Jennifer Tousignant Sells 14,212 Shares - MarketBeat

Aug 20, 2026

Viridian Therapeutics (VRDN) legal chief sells 14,212 shares - Stock Titan

Aug 20, 2026

Viridian (VRDN) Latest Quarter: Reported Results Sit Close to Expectations; Session Move: The Stock Ends Down 1.21% in Latest TradingEarnings Preview - Vinanet

Aug 20, 2026

Steven Cohen’s Point72 discloses Viridian stake (VRDN) - Stock Titan

Aug 20, 2026

Viridian Therapeutics (VRDN) Could Be 83% Undervalued On Fresh Earnings Numbers - Sahm

Aug 20, 2026

ETFs Investing in Viridian Therapeutics, Inc. Stocks - TradingView

Aug 20, 2026

Handelsbanken Fonder AB Invests $834,000 in Viridian Therapeutics, Inc. $VRDN - MarketBeat

Aug 20, 2026

Aug 19, 2026

Viridian (NASDAQ: VRDN) insider to sell 14,212 shares in August 2026 - Stock Titan

Aug 19, 2026

GSA Capital Partners LLP Invests $903,000 in Viridian Therapeutics, Inc. $VRDN - MarketBeat

Aug 19, 2026

Aug 18, 2026

Viridian (NASDAQ: VRDN) CMO acquires 40K shares via option - Stock Titan

Aug 18, 2026

93,414 Shares in Viridian Therapeutics, Inc. $VRDN Purchased by Merck & Co. Inc. - MarketBeat

Aug 18, 2026

1,175,906 Shares in Viridian Therapeutics, Inc. $VRDN Bought by Rice Hall James & Associates LLC - MarketBeat

Aug 18, 2026

Bank of America Corp DE Acquires 173,498 Shares of Viridian Therapeutics, Inc. $VRDN - MarketBeat

Aug 18, 2026

Aug 14, 2026

Viridian Therapeutics Stock Price Forecast. Should You Buy VRDN? - StockInvest.us

Aug 14, 2026

Paradigm BioCapital reports 6.1% Viridian (VRDN) stake and 5.3% held by offshore fund - Stock Titan

Aug 14, 2026

Kynam Capital group (VRDN) discloses shared power over 6.45M Viridian shares - Stock Titan

Aug 14, 2026

T. Rowe Price Associates (VRDN) discloses 5.2% Viridian Therapeutics ownership in 13G - Stock Titan

Aug 14, 2026

Deep Track group reports 3.25% Viridian Therapeutics (VRDN) ownership in latest filing - Stock Titan

Aug 14, 2026